Publications

Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASH

 53
Dual inhibition of ACLY and ACSS2 by EVT0185 reduces steatosis, hepatic stellate cell activation, and fibrosis in mouse models of MASH

Tags:

Previous Article

Blood test can to identify cancer in patients with non-specific symptoms

Next Article

New drug candidate reverses metabolic liver disease and fibrosis

Related Posts

Understanding mitochondrial protein import: a revised model of the presequence translocase

Understanding mitochondrial protein import: a revised m...

 107

Human heart-macrophage assembloids mimic immune-cardiac interactions and enable arrhythmia disease modeling

Human heart-macrophage assembloids mimic immune-cardiac...

 37

A cholinergic spinal pathway for the adaptive control of breathing

A cholinergic spinal pathway for the adaptive control o...

 106